New Penthrox Inhaler Launches for Pain Relief in Conscious Patients

A new inhaler designed to provide emergency relief from moderate to severe pain in conscious patients has been launched. The Penthrox inhaler, which administers the analgesic drug methoxyflurane, is approved for use in individuals aged six years and older experiencing trauma and associated pain. The device is intended for self-administration under the supervision of trained health care professionals.

The Penthrox inhaler operates by allowing patients to inhale vapours of the drug through a handheld device. As patients breathe in, Penthrox is released, providing immediate analgesic effects. The inhaler features an Activated Carbon Chamber, which adsorbs exhaled vapours, enhancing safety and reducing environmental exposure to the drug.

Patients will receive a single-use bottle containing 3 ml of Penthrox for administration. While a second bottle may be used if necessary, safety guidelines recommend a maximum of 6 ml in a single day, with a total weekly limit of 15 ml. The device facilitates rapid pain relief, typically beginning within 6–10 inhalations for adults, while children may require additional inhalations to achieve effective pain control.

Usage Guidelines and Recommendations

To ensure optimal pain management, patients are encouraged to inhale intermittently and to assess their own pain levels. This self-titration approach allows individuals to control their dosage for adequate analgesia. Continuous inhalation from the 3 ml bottle can provide relief for approximately 25-30 minutes, while intermittent inhalation may extend this duration.

It is crucial for patients to use the lowest effective dose to manage pain, as outlined in the product’s guidelines. The Penthrox inhaler represents a significant advancement in emergency pain relief, particularly in settings where rapid access to analgesics is essential.

For health care professionals and patients seeking more information, a full Summary of Product Characteristics is available, detailing the inhaler’s specifications and safety information.